0001461695-15-000002.txt : 20151013 0001461695-15-000002.hdr.sgml : 20151012 20151013122227 ACCESSION NUMBER: 0001461695-15-000002 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20151013 DATE AS OF CHANGE: 20151013 EFFECTIVENESS DATE: 20151013 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Nora Therapeutics, Inc. CENTRAL INDEX KEY: 0001461695 IRS NUMBER: 830509710 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-249197 FILM NUMBER: 151155420 BUSINESS ADDRESS: STREET 1: 530 LYTTON AVENUE, 2ND FLOOR CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: 1-650-479-5331 MAIL ADDRESS: STREET 1: 530 LYTTON AVENUE, 2ND FLOOR CITY: PALO ALTO STATE: CA ZIP: 94301 D 1 primary_doc.xml X0707 D LIVE 0001461695 Nora Therapeutics, Inc. 530 LYTTON AVENUE, 2ND FLOOR PALO ALTO CA CALIFORNIA 94301 1-650-479-5331 DELAWARE None None Corporation true Jeffrey K. Tong c/o Nora Therapeutics, Inc. 530 Lytton Avenue, 2nd Floor Palo Alto CA CALIFORNIA 94301 Executive Officer Director Dennis Fenton c/o Nora Therapeutics, Inc. 530 Lytton Avenue, 2nd Floor Palo Alto CA CALIFORNIA 94301 Director David Schnell c/o Nora Therapeutics, Inc. 530 Lytton Avenue, 2nd Floor Palo Alto CA CALIFORNIA 94301 Director Chen Yu c/o Nora Therapeutics, Inc. 530 Lytton Avenue, 2nd Floor Palo Alto CA CALIFORNIA 94301 Director Donald Hayden, Jr. c/o Nora Therapeutics, Inc. 530 Lytton Avenue, 2nd Floor Palo Alto CA CALIFORNIA 94301 Director Martin Vogelbaum c/o Nora Therapeutics, Inc. 530 Lytton Avenue, 2nd Floor Palo Alto CA CALIFORNIA 94301 Director Anupam Dalal c/o Nora Therapeutics, Inc. 530 Lytton Avenue, 2nd Floor Palo Alto CA CALIFORNIA 94301 Director Joseph L. Turner, Jr. c/o Nora Therapeutics, Inc. 530 Lytton Avenue, 2nd Floor Palo Alto CA CALIFORNIA 94301 Director Biotechnology Decline to Disclose 06b false 2015-09-29 false true true false 0 3000000 1000000 2000000 false 6 0 0 0 false Nora Therapeutics, Inc. /s/ Jeffrey K. Tong Jeffrey K. Tong President & CEO 2015-10-13